Nephrotoxicity of anti-angiogenesis drugs
- Authors: Grechukhina K.S.1,2, Chebotareva N.V.3, Krasnova T.N.1
-
Affiliations:
- Lomonosov Moscow State University
- Loginov Moscow Clinical Scientific Center
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 92, No 6 (2020)
- Pages: 93-98
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/35008
- DOI: https://doi.org/10.26442/00403660.2020.06.000672
- ID: 35008
Cite item
Full Text
Abstract
Neoangiogenesis is a basic factor for most physiological as well as pathological processes i.e. tumor metastases. The most important is vascular endothelium growth factor (VEGF) and its’ receptors (VEGFR1/2) in angiogenesis processes. Nowadays antiangiogenic agents (which inhibit VEGF like bevacizumab neither VEGFR2 like ramucirumab) are widely used in very different chemotherapeutic regimens in clinical oncology. The signalling pathway VEGF-VEGFR plays a crucial role in supporting of adequate kidney function. Appearance of antiangiogenic drugs led to adverse nephrotoxic effects: arterial hypertension, proteinuria, rarely – nephrotic syndrome, and kidney dysfunction. Various hystological variants of nephropathy are described, however, in most cases, signs of thrombotic microangiopathy of the renal vessels are noted. This literature review discusses mechanisms, clinical and morphological aspects of nephropathy associated with antiangiogenic drugs.
Full Text
##article.viewOnOriginalSite##About the authors
Katerina S. Grechukhina
Lomonosov Moscow State University; Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0002-0616-5477
аспирант каф. внутренних болезней, мл. науч. сотр. отд-ния химиотерапии, врач-онколог
Russian Federation, MoscowNatalia V. Chebotareva
Sechenov First Moscow State Medical University (Sechenov University)
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0003-2128-8560
д.м.н. проф., каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowTatyana N. Krasnova
Lomonosov Moscow State University
Email: dr.grechukhina@gmail.com
ORCID iD: 0000-0002-7647-3942
зав. каф. внутренних болезней
Russian Federation, MoscowReferences
- Светозарский Н.Л., Артифексова А.А., Светозарский С.Н. Фактор роста эндотелия сосудов: биологические свойства и практическое значение (обзор литературы). Journal of Siberian Medical Sciences. 2019;4:4-11 [Svetozarskiy N, Artifeksova A, Svetozarskiy S. Vascular endothelial growth factor: biological features and practical significance (literature review). Journal of Siberian Medical Sciences. 2019;4:4-11 (In Russ.)].
- Eremina V, Jefferson J, Kowalewska J. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129-36. doi: 10.1056/NEJMoa0707330
- Niu G, Chen X. Vascular Endothelial Growth Factor as an Anti-angiogenic Target for Cancer Therapy. Cur Drug Targets. 2010;11(8):1000-17. doi: 10.2174/138945010791591395
- Мещеряков А.А. Антиангиогенная терапия диссеминированного колоректального рака. Современная онкология. 2003;15(3):12-5 [Mesheryakov A. Antiangionenic therapy of disseminated colorectal cancer. Journal of Modern Oncology. 2003;15(3):12-5 (in Russ.)].
- Трякин А.А. Таргетная терапия колоректального рака, рака желудка и поджелудочной железы. Практическая онкология. 2010;11(3):143-50 [Tryakin A. Target therapy of colorectal, gastric and pancreatic cancers. Practical oncology. 2010;11(3):143-50 (In Russ.)].
- Giantonio B, Catalano P, Meropol N. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;20:1539-44. doi: 10.1200/JCO.2006.09.6305
- Pastorino A, Di Bartolomeo M, Maiello E, et al. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Clin Colorectal Cancer. 2018;17(3):e457-e470. doi: 10.1016/j.clcc.2018.03.002
- Tabernero J, Takayuki Y, Cohn A. Ramucirumab versus placebo in combination with second- line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:e262. doi: 10.1016/S1470-2045(15)70127
- Toriu A, et al. Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report. Case Rep Oncol. 2019;12:391-400. doi: 10.1159/00050071
- Maitland M, Bakris G, Black H, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596-604. doi: 10.1093/jnci/djq091
- Vaidya V, Ozer J, Frank D, et al. Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies. Nat Biotechnol. 2010;28(5):478-85. doi: 10.1038/nbt.1623
- Arnold D, Fuchs C, Tabernero J, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017;28:2932-42. doi: 10.1093/annonc/mdx514
- Qi W, Shen Z, Tang L. Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis. Clin Drug Investig. 2014;34:231-40. doi: 10.1007/s40261-014-0174-5
- Feldman D, Baum M, Ginsberg M, et al. Phase I trial of bevacizumab plus escalated doses ofsunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432-9. doi: 10.1200/JCO.2008.19.0108
- Azad N, Posadas E, Kwitkowski V, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008;26:3709-14. doi: 10.1200/JCO.2007.10.8332
- Wu S, Chen J, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:117-23. doi: 10.1016/j.eururo.2018.05.002
- Gupta S, Parsa V, Heilbrun L, et al. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs. 2011;22:794-800. doi: 10.1097/CAD.0b013e328346af0d
- Miura S, Fujino M, Matsuo Y, et al. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res. 2005;28:147-53. doi: 10.1291/hypres.28.147
- Dirix LY, Maes H, Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol. 2007;18:1121-2. doi: 10.1093/annonc/mdm205
- Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-8. doi: 10.1074/jbc.C300012200
- Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707-16. doi: 10.1172/JCI17423
- Zhu X, Wu S, Dahut W, Parikh C. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186-93. doi: 10.1053/j.ajkd.2006.11.039
- Yang J, Haworth L, Sherry R, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34. doi: 10.1056/NEJMoa021491
- Patel T, Morgan J, Demetri G, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100:282-4. doi: 10.1093/jnci/djm311
- Miller K, Chap L, Holmes F, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-9. doi: 10.1200/JCO.2005.05.098
- Мещеряков А.А. Лечение и профилактика побочных эффектов антиангиогенной терапии у больных метастатическим колоректальным раком. Рос. онкологический журн. 2017;22(3):164-8 [Mesheryakov A. Treatment and prophylaxis of adverse events of antiogenic therapy in patients with colorectal cancer. Russian oncological journal. 2017;22(3):164-8 (In Russ.)]. doi: 10.18821/1028-9984-2017-22-3-164-168
- Eremina V, Baelde H, Quaggin S. Role of the VEGF – a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiology. 2007;106(2):32-7. doi: 10.1159/000101798
- Maynard S, Min J, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-58. doi: 10.1172/JCI17189
- Abrahamson D. Glomerulogenesis in the developing kidney. Semin Nephrol. 1991;4(11):375-89.
- Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707-16. doi: 10.1172/JCI17423
- Hara A, Wada T, Furuchi K, et al. Blockade of VEGF accelerates proteinuria via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int. 2006;69(11):1986-95. doi: 10.1038/sj.ki.5000439
- Hanna R, et al. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572-80. doi: 10.1016/j.kint.2019.02.042
- Diabetic Retinopathy Clinical Research Network, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-7. doi: 10.1016/j.ophtha.2007.05.062
- Georgalas I, Papaconstantinou D, Papadopoulos K, et al. Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease – A Possible Side Effect? Cur Drug Safety. 2014;9:156. doi: 10.2174/1574886309666140211113635
- Khneizer P, Gebran T, Al-Taee M, et al. Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration. J Nephropathol. 2017;6(3):134-7. doi: 10.15171/jnp.2017.23
- Morale E, Moliz C, Gutierrez E. Renal damage associated to intravitreal administration of ranibizumab. Nefrología (English Edition). 2017;37(6):653-5. doi: 10.1016/j.nefroe.2017.10.007
- Eremina V, Quaggin S. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol. 2010;30:582-90. doi: 10.1016/j.semnephrol.2010.09.006
- Horowitz J, Rivard A, van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997;17:2793-800. doi: 10.1161/01.atv.17.11.2793
- Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24:682-5. doi: 10.1093/ndt/gfn657
- Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22:1481-2. doi: 10.1093/ndt.gfl565
- Estrada C, Maldonado A, Mallipattu S. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities. JASN. 2019;30(2):187-200. doi: 10.1681/ASN.2018080853
- Vicky B, Katarina M, David K. Thrombotic Microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300–17. doi: 10.2215/CJN.00620117
- Shimamura Y, Maeda T, Takizawa H. Bevacizumab-induced thrombotic microangiopathy and nephrotic syndrome. Clin Exp Nephrol. 2019;23:142-3. doi: 10.1007/s10157-018-1596-9
- Fujii T, Kawaasoe K, Tonooka A, et al. Nephrotic syndrome associated with ramucirumab therapy. A single-center case series and literature review. Medicine (Baltimore). 2019;98(27):e16236. doi: 10.1097/MD.0000000000016236
- Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807-15. doi: 10.1093/annonc/mdn713
- Pfister F, Amann K, Daniel C, et al. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology. 2018;73(6):990-1001. doi: 10.1111/his.13716
- Yamada R, Okawa T, Matsuo K, et al. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report. BMC Nephrol. 2019;20(1):14. doi: 10.1186/s12882-018-1194-9
- Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother. 2007;5:341-4. doi: 10.1186/s12882-018-1194-9
- Nasr S, Snyder R, Bhagat G, Markowitz G. Chronic lymphocytic leukemia and cryoglobulinemic glomerulonephritis. Kidney Int. 2007;71:93. doi: 10.1038/sj.ki.5001891
- Costero O, Picazo M, Zamora P, et al. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant. 2010;25:1001-3. doi: 10.1093/ndt/gfp666
- Pellé G, Shweke N, Duong Van Huyen J, et al. Systemic and Kidney Toxicity of Intraocular Administration of Vascular Endothelial Growth Factor Inhibitors. Am J Kidney Dis. 2011;579(5):756-9. doi: 10.1053/j.ajkd.2010.11.030
- Valdivia M, Mendoza M, Toro Prieto T, et al. Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab. Nefrología (English Edition). 2014;34(3):373-424. doi: 10.3265/Nefrologia.pre2014.Mar.12388
- Hanna R, Lopez E, Wilson J, et al. Minimal change disease onset observed after bevacizumab administration. Clin Kidney J. 2016;9(2):239-44. doi: 10.1093/ckj/sfv139
![](/img/style/loading.gif)